Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating on February 12.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
David Risinger has given his Buy rating due to a combination of factors, primarily focusing on the undervaluation of AnaptysBio’s assets. Despite the company’s market cap being only slightly above its cash reserves, AnaptysBio has a promising portfolio, particularly highlighted by the positive Phase 2b results for rosnilimab in rheumatoid arthritis and favorable perceptions of its BDCA2 candidate.
Rosnilimab showed more impressive results than competitor Lilly’s peresolimab in cross-trial comparisons, with a higher percentage of patients achieving low disease activity. Additionally, the collaboration between Royalty Pharma and Biogen on the BDCA2 antibody further underscores confidence in AnaptysBio’s pipeline. Potential financial gains from royalty streams related to GSK add to the overall positive outlook, supporting the Outperform rating on ANAB shares.
In another report released on February 12, Wells Fargo also maintained a Buy rating on the stock with a $51.00 price target.
ANAB’s price has also changed dramatically for the past six months – from $33.330 to $19.290, which is a -42.12% drop .